Risk Of Developing Liver Cancer After HCV Treatment

Friday, March 17, 2017

How do insurers decide what medicines to pay for?

How do insurers decide what medicines to pay for?
By: TOM MURPHY, Associated Press March 17, 2017

Whether a drug even gets on the list can depend on whether a similar medicine is already in the market. When the ground-breaking hepatitis C treatments Sovaldi and Harvoni from Gilead Sciences debuted a few years ago, Express Scripts had to include them. They cost more than $80,000 for a course of treatment, but the drugs essentially cure a debilitating disease and they had no competition.

But once the drugmaker AbbVie produced a third option, Viekira Pak, with a similar cure rate, Express Scripts was able to negotiate a price discount and switched to covering only Viekira Pak.
Continue reading...

No comments:

Post a Comment